-
Merck's K-drug combination therapy for first-line treatment of esophageal cancer receives positive opinions from EU CHMP
Time of Update: 2021-06-01
Reference source: Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
-
CStone's PD-L1 antibody non-small cell lung cancer global phase 3 clinical registration reaches the primary endpoint
Time of Update: 2021-06-01
According to the press release, the primary endpoint is a multi-center, randomized, double-blind phase 3 clinical trial called GEMSTONE-301, which aims to evaluate sugarizumab as a consolidation therapy in concurrent or sequential radiotherapy and chemotherapy Efficacy and safety in locally advanced/unresectable stage III non-small cell lung cancer patients without disease progression afterwards.
-
The second 1 billion Chinese patent medicine plaster was born!
Time of Update: 2021-06-01
The second 1 billion Chinese patent medicine plaster was born Sales of Yunnan Baiyao Ointment in Public Medical Institutions in China in Recent Years Source: Terminal competition landscape of China's public medical institutions Yunnan Baiyao Ointment is an exclusive product of Yunnan Baiyao, which is used for bruises, blood stasis, swelling pain, and rheumatic pain.
-
Chinese researchers have invented a gene editing technology for rape and cabbage that does not rely on genetic transformation
Time of Update: 2021-06-01
This method breaks the reliance on genetic transformation of rape and cabbage gene editing technology, edits the genes of rape and cabbage directly through pollination, and obtains mutant materials without genetically modified elements, which is a high-yield, high-quality, and multi-resistant new variety The cultivation provides new technical reserves.
-
Hengrui Medicine's 5 anti-tumor studies are selected for Oral link
Time of Update: 2021-06-01
0 months of the placebo group; the median progression-free survival In terms of (PFS), the carrelizumab group was 6.
In terms of side effects, the incidence of ≥3 treatment-related adverse events (TRAEs) was 93% in the carrelizumab group and 90% in the placebo group.
-
Li Shuhong resigned as director of Jiangsu Haobo Biomedical and other positions
Time of Update: 2021-06-01
Li Shuhong resigned as a director, secretary of the board of directors and chief financial officer due to personal reasons, and the handover has been completed a few days ago.
-
Quantitative and QMM--an alternative method to accelerate drug development
Time of Update: 2021-06-01
Today, more organizations will be able to adopt QMM, and agencies such as WHO or FDA are currently promoting QMM, so it is becoming more recognized in the development and review of modern generic drugs.
-
Sialon Pharmaceuticals: The company's omeprazole sodium for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-01
The main indication for omeprazole sodium for injection that passed the generic drug consistency evaluation this time is for the treatment of acute upper gastrointestinal bleeding caused by duodenal ulcer, gastric ulcer, acute gastric mucosal lesions, and compound ulcers.
-
Luye Pharma's innovative drug Liss' Mingdo Day transdermal patch obtained EU multi-country marketing authorization qualification
Time of Update: 2021-06-01
Luye Pharmaceutical Group announced that its self-developed innovative preparation, Liss’ Mindo Day transdermal patch, has successfully passed the EU decentralized review process.
-
Huadong Medicine's Class 1 new drug IMGN853 was approved for a pivotal single-arm clinical trial
Time of Update: 2021-06-01
The application for the first clinical trial of IMGN853 in China was approved on March 30, 2021, including the above-mentioned international multi-center phase III study and a phase I study evaluating safety, tolerability and pharmacokinetics in Chinese adult patients The criteria for patient entry included platinum-resistant advanced high-grade epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer patients with high expression of folate receptor alpha.
-
The 4th domestically produced! CP Tianqing wins $800 million in anti-tumor drugs
Time of Update: 2021-06-01
On May 24, the official website of the State Food and Drug Administration showed that sunitinib malate capsules of Chia Tai Tianqing Pharmaceutical Group were approved for marketing, and the product was the fourth domestically approved product.
-
East Sunshine: Rivaroxaban tablets obtained drug registration certificate
Time of Update: 2021-06-01
The product is Rivaroxaban tablets, one of 27 generic drugs purchased by the company's holding subsidiary, Yichang Dongguang Yangtze Pharmaceutical Co.
-
Lunan Pharmaceutical ``Axitinib'' was approved for listing
Time of Update: 2021-06-01
This time, Lunan Pharmaceutical's axitinib tablet was approved, which is the first imitation of the product, and it will bring more treatment options for patients with advanced renal cancer.
-
Ningxia wolfberry regional public brand logo, slogan, and mascot released
Time of Update: 2021-06-01
Medical Network, May 27 News On May 26, Wang Zixin, deputy director of the Ningxia Forestry and Grassland Bureau, officially announced the press conference for the Ningxia wolfberry regional public brand launch and the preparations for the 4th wolfberry industry expo held by the Information Office of the Ningxia Hui Autonomous Region Government.
-
Shortage of drugs to ensure supply and price stabilization. Recent work has been announced. Supervision and law enforcement have been stepped up
Time of Update: 2021-06-01
The State-owned Assets Supervision and Administration Commission of the State Council has guided the establishment of a dynamic tracking mechanism for the supply of shortage drugs, and has adopted various measures to ensure sufficient inventory of shortage drugs to ensure supply.
-
"Millennium Medicine Capital" Hebei Anguo: 52.01 million yuan prize for outstanding private enterprises to encourage innovation and help growth
Time of Update: 2021-06-01
(Finish) Medical Network News on May 28th, 27th, Anguo City, Hebei Province held a private enterprise innovation and development conference.
(Finish) Medical Network News on May 28th, 27th, Anguo City, Hebei Province held a private enterprise innovation and development conference.
-
NASH treatment drug phase IIb study failed, stock price plummeted by 40%
Time of Update: 2021-06-01
Article source: Medical Rubik's Cube InfoOn May 24, NGM Biopharmaceuticals announced the data of a phase IIb clinical study code-named ALPINE 2/3, which aims to evaluate aldafermin in the treatment of non-alcoholic steatohepatitis (NASH) with stage 2 or stage 3 liver fibrosis (F2/ F3) Efficacy of patients.
-
Decitabine for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-01
In 2008, it was approved to be imported and marketed in China for the treatment of myelodysplastic syndrome (MDS); in 2012, it was approved by the European Drug Administration for the treatment of elderly acute myeloid leukemia.
-
Another pharmaceutical company stopped the science and technology innovation board
Time of Update: 2021-06-01
Recently, the Shanghai Stock Exchange issued an announcement stating that it would terminate the decision to review the initial public offering of shares of Suzhou Ruibo Biotechnology Co.
Regarding the Withdrawal of Initial Public Offering and Listing on the Sci-tech Innovation Board" and the "Application Documents" Guotai Junan Securities Co.
-
11 medicines are higher than the lowest prices in the five provinces and cities to withdraw from the Internet soon!
Time of Update: 2021-06-01
The price is higher than the lowest price in the five provinces and cities, and the companies involved include Jianlang Pharmaceutical, Jichuan Pharmaceutical, Wanle Pharmaceutical, Jinyuan Pharmaceutical, Baiyunshan Pharmaceutical General Factory, and Pfizer.
